FDA Adcomm Backs Accelerated Approval of Biogen’s Tofersen in SOD1-ALS

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that tofersen’s effect on neurofilament light chain (NfL) could be a reasonable predictor of clinical benefit.